531 related articles for article (PubMed ID: 12748172)
21. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
[TBL] [Abstract][Full Text] [Related]
22. Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase.
Tartari CJ; Gunby RH; Coluccia AM; Sottocornola R; Cimbro B; Scapozza L; Donella-Deana A; Pinna LA; Gambacorti-Passerini C
J Biol Chem; 2008 Feb; 283(7):3743-50. PubMed ID: 18070884
[TBL] [Abstract][Full Text] [Related]
23. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis.
Ma Z; Cools J; Marynen P; Cui X; Siebert R; Gesk S; Schlegelberger B; Peeters B; De Wolf-Peeters C; Wlodarska I; Morris SW
Blood; 2000 Mar; 95(6):2144-9. PubMed ID: 10706887
[TBL] [Abstract][Full Text] [Related]
24. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
[TBL] [Abstract][Full Text] [Related]
25. Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma.
Wu F; Wang P; Zhang J; Young LC; Lai R; Li L
Mol Cell Proteomics; 2010 Jul; 9(7):1616-32. PubMed ID: 20393185
[TBL] [Abstract][Full Text] [Related]
26. Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity.
Hernández L; Beà S; Bellosillo B; Pinyol M; Falini B; Carbone A; Ott G; Rosenwald A; Fernández A; Pulford K; Mason D; Morris SW; Santos E; Campo E
Am J Pathol; 2002 Apr; 160(4):1487-94. PubMed ID: 11943732
[TBL] [Abstract][Full Text] [Related]
27. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
28. The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.
Hegazy SA; Wang P; Anand M; Ingham RJ; Gelebart P; Lai R
J Biol Chem; 2010 Jun; 285(26):19813-20. PubMed ID: 20424160
[TBL] [Abstract][Full Text] [Related]
29. EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53.
Uchihara Y; Tago K; Tamura H; Funakoshi-Tago M
Mol Oncol; 2021 Jan; 15(1):167-194. PubMed ID: 33040459
[TBL] [Abstract][Full Text] [Related]
30. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
31. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma.
Trinei M; Lanfrancone L; Campo E; Pulford K; Mason DY; Pelicci PG; Falini B
Cancer Res; 2000 Feb; 60(4):793-8. PubMed ID: 10706082
[TBL] [Abstract][Full Text] [Related]
32. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
Nieborowska-Skorska M; Slupianek A; Xue L; Zhang Q; Raghunath PN; Hoser G; Wasik MA; Morris SW; Skorski T
Cancer Res; 2001 Sep; 61(17):6517-23. PubMed ID: 11522649
[TBL] [Abstract][Full Text] [Related]
33. The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation.
Hübinger G; Scheffrahn I; Müller E; Bai R; Duyster J; Morris SW; Schrezenmeier H; Bergmann L
Exp Hematol; 1999 Dec; 27(12):1796-805. PubMed ID: 10641597
[TBL] [Abstract][Full Text] [Related]
34. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system.
Iwahara T; Fujimoto J; Wen D; Cupples R; Bucay N; Arakawa T; Mori S; Ratzkin B; Yamamoto T
Oncogene; 1997 Jan; 14(4):439-49. PubMed ID: 9053841
[TBL] [Abstract][Full Text] [Related]
35. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells.
Ruchatz H; Coluccia AM; Stano P; Marchesi E; Gambacorti-Passerini C
Exp Hematol; 2003 Apr; 31(4):309-15. PubMed ID: 12691918
[TBL] [Abstract][Full Text] [Related]
36. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
37. NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.
Leventaki V; Drakos E; Medeiros LJ; Lim MS; Elenitoba-Johnson KS; Claret FX; Rassidakis GZ
Blood; 2007 Sep; 110(5):1621-30. PubMed ID: 17416736
[TBL] [Abstract][Full Text] [Related]
38. Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas.
Colomba A; Courilleau D; Ramel D; Billadeau DD; Espinos E; Delsol G; Payrastre B; Gaits-Iacovoni F
Oncogene; 2008 Apr; 27(19):2728-36. PubMed ID: 17998938
[TBL] [Abstract][Full Text] [Related]
39. NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis.
Kreutmair S; Lippert LJ; Klingeberg C; Albers-Leischner C; Yacob S; Shlyakhto V; Mueller T; Mueller-Rudorf A; Yu C; Gorantla SP; Miething C; Duyster J; Illert AL
Front Oncol; 2022; 12():875117. PubMed ID: 35646639
[TBL] [Abstract][Full Text] [Related]
40. Model of inhibition of the NPM-ALK kinase activity by herbimycin A.
Turturro F; Arnold MD; Frist AY; Pulford K
Clin Cancer Res; 2002 Jan; 8(1):240-5. PubMed ID: 11801565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
